期刊文献+

二甲亚砜与第二信使效应剂对深低温冻存血小板膜CD42b、CD62p表达的影响 被引量:2

EFFECTS OF DIMETHYL SULFOXIDE AND SECOND-MESSENGER EFFECTOR ON CRYOPRESERVED PLATELET MEMBRANE EXPRESSIONS CD42b AND CD62p
下载PDF
导出
摘要 ①目的观察体积分数0.02二甲亚砜(DMSO)联合第二信使效应剂(ThromboSol,TS)在-196 ℃时对浓缩血小板膜CD42b、CD62p表达的影响,并了解体积分数0.02 DMSO+TS对浓缩血小板的长期(6个月)保存效果.②方法分别应用体积分数0.02 DMSO、体积分数0.06 DMSO、体积分数0.02 DMSO+TS作为冻存液-196 ℃冷冻保存浓缩血小板,并在冻存后1、3及6个月时分别取出复温,流式细胞仪检查血小板膜CD42b、CD62p表达水平.③结果冻存后1、3及6个月,体积分数0.02 DMSO+TS组与体积分数0.06 DMSO组血小板CD42b的表达水平差异无显著性(F=3.13~5.01,q=1.12~1.76,P>0.05),两者均高于体积分数0.02 DMSO组(q=3.17~4.06,P<0.05);但与新鲜组相比,3组冷冻保存血小板CD42b表达水平均有所下降(q=3.09~4.15,P<0.05).体积分数0.02 DMSO+TS组CD62p的表达水平低于体积分数0.06 DMSO组和体积分数0.02 DMSO组,差异有显著性(F=5.75~9.77,q=3.20~4.34,P<0.05),后两组差异无统计学意义(q=1.55~2.02,P>0.05);与新鲜组相比,3组均明显升高,差异有显著性(q=4.85~7.35,P<0.01).④结论第二信使效应剂的应用降低了DMSO的使用浓度,在抑制血小板的体外激活方面,体积分数0.02 DMSO+TS的效果优于体积分数0.06 DMSO,且长期(6个月)保存效果稳定. Objective To observe the effect of cryopreservation with 0.02 dimethyl sulfoxide(DMSO) plus ThromboSol, a mixture of second-messenger effectors, on platelet membrane CD42b and CD62p, and to investigate the long-term (6 months) preservation effect of the platelet storage solution. Methods Platelet concentrates were treated with 0.02 DMSO, 0.06 DMSO and 0.02 DMSO plus ThromboSol, and then placed in liquid nitrogen. The samples were thawed and expression levels of CD42b and CD62p on platelet membrane were analyzed after one month, three months and six months, respectively. Results The platelet expression level of CD42b in the 0.02 DMSO-plus-ThromboSol group was not significantly different from those in the 0.06 DMSO group (F=3.13-5.01,q=1.12-1.76, P>0.05), and the levels of both groups were higher than those in the 0.02 DMSO group (q=3.17-4.06, P<0.05) one, three and six months later. The CD42b levels of the three groups were lower than those of the fresh platelets (q=3.09-4.15, P<0.05). The platelets treated with 0.02 DMSO plus ThromboSol showed statistically lower CD62p expression than those frozen with 0.06 DMSO and 0.02 DMSO(F=5.75-9.77,q=3.20-4.34,P<0.05). There were no obvious differences in CD62p expression between platelets treated with 0.06 DMSO and 0.02 DMSO (q=1.55-2.02, P>0.05). But the three groups of frozen platelets showed significant increase of surface expression of CD62p in comparison to the fresh platelets (F=3.95, q=4.85-7.35, P<0.01). Conclusion The second-messenger effectors could reduce the DMSO concentration. The 0.02 DMSO plus ThromboSol is superior to 0.06 DMSO in inhibiting the activation of platelets, and is stable within six months.
出处 《齐鲁医学杂志》 2005年第1期25-27,共3页 Medical Journal of Qilu
基金 山东省卫生厅科研基金资助项目(1998CA2CKA1)
关键词 血小板 二甲基亚砜 低温保存 第二信使效应剂 CD42B CD62P platelets dimethyl sulfoxide cryopreservation second-messenger effectors CD42b CD62p
  • 相关文献

参考文献14

  • 1Corash L.Inactivation of viruses,bacteria,protozoa and leukocytes in platelet concentrates[J].Vox Sang,1998, 74:173.
  • 2Alvarez FE, Rogge KJ, Tarrand J, et al. Bacterial contamination of cellular blood components. A retrospective review at a large cancer center[J]. Ann Clin Lab Sci, 1995, 25:283.
  • 3Connor J, Currie LM, Allan H, et al. Recovery of in vitro functional activity of platelet concentrates stored at 4℃ and treated with second messenger effectors[J]. Transfusion, 1996, 36:691.
  • 4Currie LM, Harper JR, Allan H, et al. Inhibition of cytokine accumulation and bacterial growth during storage of platelet concentrates at 4 ℃ with retention of in vitro functional activity[J]. Transfusion, 1997, 37:18.
  • 5Rivera J, Lozano ML, Corral J, et al. Quality assessment of platelet concentrates supplemented with second messenger effectors[J]. Transfusion, 1999, 39:135.
  • 6Angolini A, Dragani A, Berardi A, et al. Evaluation of four different methods for platelet freezing in vitro and in vivo studies[J]. Vox Sang, 1992, 62: 146.
  • 7Gao DY, Neff K, Xiao HY, et al. Development of optimal techniques for cryopreservation of human platelets[J]. Cryobiology, 1999, 38:225.
  • 8刘景汉,王青梅,李茨芬,殷宗健.血小板低温保存实验与临床应用研究[J].解放军医学杂志,1998,23(4):293-294. 被引量:40
  • 9孟凡会,孙青刚,刘忠强,孙波,刘竹珍,刘金兰.二甲亚砜与第二信使效应剂对深低温保存血小板聚集功能的影响[J].齐鲁医学杂志,2005,20(1):21-24. 被引量:4
  • 10Bode AP, Holme S, Heaton WA, et al. Extended storage of platelets in an artificial medium with the platelet activation inhibitors prostaglandin E1 and the ophylline[J]. Vox Sang, 1996, 60:105.

二级参考文献20

  • 1刘景汉,解放军医学杂志,1993年,18卷,456页
  • 2刘景汉,解放军医学杂志,1992年,17卷,191页
  • 3王宇,吉林医药,1991年,12卷,21页
  • 4刘作斌,解放军军区进修学院学报,1990年,11卷,31页
  • 5刘景汉,解放军医学杂志,1989年,14卷,106页
  • 6Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet concentrates[J]. Vox Sang, 1998, 74: 173.
  • 7Alvarez FE, Rogge KJ, Tarrand J, et al. Bacterial contamination of cellular blood components. A retrospective review at a large cancer center[J]. Ann Clin Lab Sci, 1995, 25:283.
  • 8Connor J, Currie LM, Allan H, et al. Recovery of in vitro functional activity of platelet concentrates stored at 4℃ and treated with second messenger effectors[J]. Transfusion, 1996, 36:691.
  • 9Currie LM, Harper JR, Allan H, et al. Inhibition of cytokine accumulation and bacterial growth during storage of platelet concentrates at 4℃ with retention of in vitro functional activity[J]. Transfusion, 1997, 37:18.
  • 10Rivera J, Lozano ML, Corral J, et al. Quality assessment of platelet concentrates supplemented with second messenger effectors[J].Transfusion, 1999, 39:135.

共引文献41

同被引文献17

  • 1孟凡会,孙青刚,刘忠强,孙波,刘竹珍,刘金兰.二甲亚砜与第二信使效应剂对深低温保存血小板聚集功能的影响[J].齐鲁医学杂志,2005,20(1):21-24. 被引量:4
  • 2张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2008:220-227.
  • 3Slichter SJ.Evidence-based platelet transfusion guidelines.Hematology Am Soc Hematol Educ Program,2007,2007:172-178.
  • 4Vadhan-Raj S,Kavanagh JJ,Freedman RS,et al.Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapyassociated severe thrombocytopenia:a randomised cross-over study.Lancet,2002,359:2145-2152.
  • 5Pedrazzoli P,Noris P,Perotti C,et al.Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia:a pilot study.Br J Haematol,2000,108:653-659.
  • 6Davis KB,Slichter SJ,Corash L.Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response:problems and a solution.Transfusion,1999,39:586-592.
  • 7D(o)hner H,Estey EH,Amadori S,et al.Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel,on behalf of the European LeukemiaNet.Blood,2010,115:453-474.
  • 8Slichter SJ,Fish D,Abrams VK,et al.Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.Blood,2005,105:847-854.
  • 9Bava ED,Barber FA.Platelet-rich plasma products in sports medicine.Phys Sportsmed,2011,39:94-99.
  • 10Krüger jP,Hondke S,Endres M,et al.Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells[J/OL].J Orthop Res,2011,29[2012-02-06].http://onlinelibrary.wiley.com/doi/10.1002/jor.22005/abstract ; jsessionidC7A95A1DAA553E703B227778481572C4.d01t04.[published online ahead of print November 4,2011].

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部